Table 2 Current clinical studies investigating nanotechnology for cancer therapies

NCT04852367

PanDox: Targeted Doxorubicin in pancreatic tumors

Pancreatic ductal adenocarcinoma/pancreatic cancer stage IV/pancreatic cancer non-resectable/pancreatic cancer metastatic

Device: focused ultrasound/Drug: Doxorubicin/Drug: ThermoDox

Phase 1

NCT04844983

A study to evaluate safety, efficacy of intralesional injection of STP705 in patients with isSCC

Squamous cell carcinoma in situ

Drug: STP705/Other: placebo saline

Phase 2

NCT04791228

A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors

Solid tumors/soft tissue sarcoma/ewing sarcoma/malignant epithelial neoplasm/rhabdomyosarcoma/wilms tumor/hepatic tumor/germ cell tumor/bone metastases

Device: magnetic resonance-guided high intensity focused ultrasound/Drug: Lyso-thermosensitive Liposomal Doxorubicin

Phase 2

NCT04751786

Dose escalation study of immunomodulatory NPs

Advanced solid tumor

Drug: PRECIOUS-01

Phase 1

NCT04676633

Open-label study for safety, tolerability, pk and anti-tumor activity of STP705 administered intratumorally in cholangiocarcinoma, hepatocellular carcinoma or liver metastases in subjects with advanced/metastatic or surgically unresectable solid tumors who are refractory to standard therapy

Hepatocellular carcinoma/liver metastases/cholangiocarcinoma

Drug: STP705

Phase 1

NCT04669808

Open label, dose escalation study for the safety and efficacy of STP705 in adult patients with basal cell carcinoma

Basal cell carcinoma

Drug: STP705

Phase 2

NCT04486833

TUSC2-NPs (GPX-001) and Osimertinib in patients with stage IV lung cancer who progressed on Osimertinib alone

Carcinoma, non-small-cell lung

Biological: Quaratusugene ozeplasmid—intravenous infusion/Drug: Osimertinib oral tablet

Phase 1/2

NCT04382898

PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Prostate cancer

Biological: W_pro1/Drug: Cemiplimab

Phase 1/2

NCT04235101

Phase I study of SYD985 with Niraparib in patients with solid tumors

Solid tumor

Drug: SYD985 + Niraparib

Phase 1

NCT04205630

SYD985 in patients with HER2-expressing recurrent, advanced or metastatic endometrial carcinoma

Endometrial cancer

Drug: SYD985

Phase 2

NCT04202705

A first-in-human dose-escalation and expansion study with the antibody–drug conjugate SYD1875

Solid tumor

Drug: SYD1875

Phase 1

NCT04163094

Ovarian cancer treatment with a liposome formulated mRNA vaccine in combination with (neo-)adjuvant chemotherapy

Ovarian cancer

Drug: W_ova1 Vaccine

Phase 1

NCT04078295

A study of E7389 liposomal formulation (E7389-LF) plus Nivolumab in participants with solid tumor

Solid neoplasms

Drug: E7389-LF/Drug: Nivolumab

Phase 1/2

NCT03774680

Targeted polymeric NPs loaded with Cetuximab and decorated with Somatostatin analogue to colon cancer

Colon cancer/colo-rectal cancer

Drug: Cetuximab NPs/Drug: Oral approved anticancer drug

Phase 1

NCT03608631

iExosomes in treating participants with metastatic pancreas cancer with KrasG12D mutation

KRAS NP_004976.2:p.G12D/metastatic pancreatic adenocarcinoma/pancreatic ductal adenocarcinoma/stage IV pancreatic cancer AJCC v8

Drug: Mesenchymal stromal cells-derived exosomes with KRAS G12D siRNA

Phase 1

NCT03418480

HPV Anti-CD40 RNA vaccine

Carcinoma, squamous cell/head and neck neoplasm/cervical neoplasm/penile neoplasms malignant

Drug: HPV vaccine

Phase 1/2

NCT03313778

Safety, tolerability, and immunogenicity of mRNA-4157 alone in participants with resected solid tumors and in combination with Pembrolizumab in participants with unresectable solid tumors

Solid tumors

Biological: mRNA-4157/Biological: Pembrolizumab

Phase 1

NCT03262935

SYD985 vs. physician's choice in participants with HER2-positive locally advanced or metastatic breast cancer

Metastatic breast cancer

Drug: (vic-)trastuzumab duocarmazine/Drug: Physician's choice

Phase 3

NCT02769962

Trial of EP0057, a nanoparticle Camptothecin with Olaparib in people with relapsed/refractory small cell lung cancer

Urothelial carcinoma/urothelial cancer/lung neoplasms/small cell lung cancer/prostate cancer

Drug: EP0057/Drug: olaparib

Phase 1/2

NCT02389985

A Study of CRLX101(NLG207) in combination with weekly Paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer

Ovarian cancer

Drug: CRLX101/Drug: Paclitaxel

Phase 1/2

NCT02316457

RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID

Breast Cancer (Triple Negative Breast Cancer (TNBC))

Biological: IVAC_W_bre1_uID/Biological: IVAC_W_bre1_uID/IVAC_M_uID

Phase 1

NCT02181075

Targeted chemotherapy using focused ultrasound for liver tumors

Liver tumor

Drug: ThermoDox¬Æ (LTLD)/Device: focused ultrasound of target liver tumor/Diagnostic Test: Pre-LTLD biopsy of target liver tumor/Diagnostic Test: Post-LTLD biopsy of target liver tumor/Diagnostic Test: Post-LTLD + FUS (Post-FUS) biopsy of target liver tumor/Device: thermometry of target tumor

Phase 1

NCT02112656

Study of ThermoDox with standardized radiofrequency ablation (RFA) for treatment of hepatocellular carcinoma (HCC)

Hepatocellular carcinoma

Drug: ThermoDox/Drug: Dummy infusion

Phase 3

NCT02022644

Study of convection-enhanced, image-assisted delivery of liposomal-irinotecan in recurrent high grade glioma

High grade glioma

Drug: Nanoliposomal irinotecan

Phase 1

NCT01861496

Phase I/II study to evaluate the safety and tolerability of LiPlaCis in patients with advanced or refractory tumors

Phase 1: advanced or refractory solid tumors/Phase 2 part: metastatic breast cancer, prostate cancer and skin cancer

Drug: LiPlaCis

Phase 1/2

NCT01591356

EphA2 siRNA in treating patients with advanced or recurrent solid tumors

Advanced malignant solid neoplasm

Drug: EphA2-targeting DOPC-encapsulated siRNA/Other: laboratory biomarker analysis/other: pharmacological study

Phase 1

NCT01437007

TKM 080,301 for primary or secondary liver cancer

Colorectal cancer with hepatic metastases/pancreas cancer with hepatic metastase/gastric cancer with hepatic metastase/breast cancer with hepatic metastase/ovarian cancer with hepatic metastase

Drug: TKM-080301

Phase 1

NCT01042379

I-SPY TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast cancer

Breast neoplasms/breast cancer/breast tumors/angiosarcoma

Drug: Standard Therapy/Drug: AMG 386 with or without Trastuzumab/Drug: AMG 479 (Ganitumab) plus Metformin/Drug: MK-2206 with or without Trastuzumab/Drug: AMG 386 and Trastuzumab/Drug: T-DM1 and Pertuzumab/Drug: Pertuzumab and Trastuzumab/Drug: Ganetespib/Drug: ABT-888/Drug: Neratinib/Drug: PLX3397/Drug: Pembrolizumab—4 cycle/Drug: Talazoparib plus Irinotecan/Drug: Patritumab and Trastuzumab/Drug: Pembrolizumab—8 cycle/Drug: SGN-LIV1A/Drug: Durvalumab plus Olaparib/Drug: SD-101 + Pembrolizumab/Drug: Tucatinib plus trastuzumab and pertuzumab/Drug: Cemiplimab/Drug: Cemiplimab plus REGN3767/Drug: Trilaciclib with or without trastuzumab + pertuzumab/Drug: SYD985 ([vic-]trastuzumab duocarmazine)/Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab/Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab

Phase 2

NCT00504998

Safety/efficacy study of Rexin-G to treat pancreatic cancer

Pancreatic cancer

Genetic: Rexin-G

Phase 1/2